InCure

InCure Therapeutics is a South Korean biotechnology company dedicated to developing first-in-class small molecule therapeutics for inflammatory and fibrotic diseases. The company's core technology focuses on the selective inhibition of Signal Transducer and Activator of Transcription 3 (STAT3), a key regulator in various pathological processes including chronic inflammation and tissue scarring. Their lead programs, IC-101 and IC-201, target Non-Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF), respectively, aiming to address significant unmet medical needs. By leveraging its proprietary drug discovery platform, InCure seeks to provide transformative treatments that modulate immune responses and prevent disease progression. The company is also exploring the potential of its STAT3 inhibitors in oncology for the treatment of various solid tumors.